
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp demonstrated solid financial performance with General Surgery sales increasing by 8.7% to $206.9 million, outperforming expectations, while Orthopedic Surgery sales rose by 2.4% to $139.0 million, also exceeding consensus estimates. The company achieved an improved operating margin of 18.6%, attributable to gross margin expansion and operational efficiencies, and is expected to continue this upward trend, with earnings per share anticipated to grow faster than revenues. Moreover, the gross margin saw a rise to 57.6%, indicating strong pricing power and cost management, despite challenges from supply chain issues.
Bears say
The financial outlook for Conmed Corp reflects a bear case scenario wherein revenue growth is anticipated to decelerate to 4% or less, primarily due to sluggish performance in AirSeal and Buffalo Filter sales, coupled with potential challenges from new product launches. Furthermore, management has guided for 2025 revenue and EPS projections that fall below consensus estimates, citing ongoing supply chain difficulties that are expected to exert pressure on operating margins. Additionally, anticipated reductions in revenue estimates for 2025 and 2026 underscore the company’s struggles with capital spending in hospitals and adverse currency effects, contributing to a negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares